Last reviewed · How we verify
Licensed Tdap vaccine
At a glance
| Generic name | Licensed Tdap vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers (PHASE2, PHASE3)
- Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Adults (PHASE3)
- Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors (PHASE2)
- Tdap Vaccine Safety for Plasma Donors (PHASE2, PHASE3)
- A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada (PHASE1)
- Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Licensed Tdap vaccine CI brief — competitive landscape report
- Licensed Tdap vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI